Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Investment firm Ashva Capital Management reveals Micron Technology as its largest holding in its latest investor letter, detailing a conviction play on the memory chip giant's long-term trajectory amid AI-driven demand and market volatility.
A recent anniversary event for 'Silicon Alley' highlighted how New York's technology sector has evolved from a concentrated downtown community into a vast, decentralized force spanning finance, AI, and e-commerce.
After a prolonged correction, Brent crude oil is showing signs of a potential trend reversal, with a forming double bottom pattern pointing toward a technical target near $95 per barrel. The shift comes amid a tightening physical market and simmering geopolitical risks.
Investment firm Giverny Capital Asset Management reduced its stake in industrial manufacturer AMETEK in Q4 2025, highlighting a disciplined approach to valuation as markets remain captivated by AI narratives. The firm's portfolio underperformed major indices, pressured by its underweight stance in mega-cap technology.
Schweiter Technologies (SWTQ) has seen significant price swings on the SIX Swiss Exchange. With its current valuation trading well above industry peers, we examine whether the stock's optimistic growth prospects justify the premium or if investors should wait for a better entry point.
Despite a brutal 50% share price plunge over three months, Reitar Logtech Holdings (NASDAQ:RITR) exhibits underlying financial resilience. While its Return on Equity appears weak, the company's aggressive reinvestment strategy has fueled a remarkable 26% net income growth over five years, starkly outperforming its struggling industry. This analysis delves into the disconnect between short-term market sentiment and the firm's long-term operational engine.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Despite a 35% monthly plunge, Hedera's HBAR shows signs of underlying buyer interest through key technical divergences. However, a critical shift in exchange flows threatens to delay any near-term price rebound, leaving the token at a pivotal juncture.
While many chase high-risk, loss-making stories, Tyler Technologies (TYL) stands out with consistent profitability and growth. We examine the key metrics and management alignment that make this software provider a stock worth watching.
The third-quarter earnings season revealed a stark divergence in performance among leading healthcare technology providers. While Omnicell impressed with strong results and a soaring stock, peers like Evolent Health and Astrana Health faced significant market headwinds despite revenue beats.
Shares of Bitmine Immersion Technologies (BMNR) have tumbled nearly 10% this week, extending a volatile trend. Trading at a significant discount to peers on a price-to-book basis, the crypto-linked firm presents a conundrum: is its low valuation a buying opportunity, or a red flag for its loss-making business model?
Despite a recent 9.4% share price decline, Bytes Technology Group (BYIT) showcases exceptional financial health with a 69% ROE, suggesting the current weakness may be a buying opportunity for patient investors.
Amidst a cautiously optimistic Asian market, companies where executives and directors hold significant stakes are drawing investor attention. We examine three high-conviction plays in semiconductors, 3D printing, and biotech where insider ownership aligns with explosive growth forecasts.
Integral Ad Science appoints Horizon Media's Bob Lord and Amazon's former video ad chief Krishan Bhatia to its board, a move analysts say sharpens its focus on the convergence of streaming, data, and advertising technology.
NextEra Energy is aggressively pursuing long-term power supply agreements with major technology firms, positioning itself as a one-stop shop for clean, reliable electricity to fuel the data center boom. Its strategy hinges on a three-pronged approach: record renewable energy additions, potential nuclear fleet expansion, and a pioneering gas plant with carbon capture technology developed with ExxonMobil.
Shares of Ethos Technologies have slumped 10.7% year-to-date, trading around $15.05. A detailed valuation analysis reveals a stark contradiction: while a discounted cash flow model suggests massive undervaluation, its price-to-earnings ratio paints a picture of overvaluation. This divergence highlights the critical debate among investors about the insurer's true worth and future trajectory.
Investment firm Tanager Wealth Management has fully divested its position in Centessa Pharmaceuticals, capitalizing on the biotech's near-60% annual surge. The move highlights strategic portfolio rebalancing as the stock's rally potentially amplified its risk profile within a diversified fund.
While both ETFs target the high-flying U.S. technology sector, a closer look reveals critical distinctions in diversification, concentration risk, and liquidity that could sway long-term portfolio outcomes.
